• Release your full potential

    Be active. Be free. Experience real-life
    superior treatment with PAD TM Technology based drugs

ABOUT US

We are committed to optimize the patient experience for patients with chronic inflammatory skin conditions by introducing novel topical therapies designed to combine fast relief of symptoms with high convenience in daily routines. Higher satisfaction and less discontinuation address the needs of patients, physicians and societies. Read more about MC2 Therapeutics.

Platform

Our PAD ™ Technology enables a new class of creams and eye drops (PAD ™ Vehicles) that offer a number of unique advantages in the development of new topical therapies. Read more about our platform.

Pipeline

Our current pipeline includes programs in major chronic inflammatory diseases such as psoriasis, atopic dermatitis, pruritus and dry and sensitive skin and eyes. Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-04

MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis

  • Wynzora™ Cream demonstrates statistically significantly better treatment efficacy compared to Daivobet® Gel.
  • Wynzora™ Cream demonstrates statistically ...

    READ FULL ARTICLE

MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis

Copenhagen, November 20th, 2019 – MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ ...

READ FULL ARTICLE

 

mc2_news-image-icon-04

MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis

Copenhagen, September 24th, 2019 – MC2 Therapeutics, a late clinical-stage pharmaceutical company focused on novel ...

READ FULL ARTICLE

mc2_news-image-icon-07

MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients with Plaque Psoriasis Treated with MC2-01 PAD TM Cream

  • Topline data are expected in Q4 2019

Copenhagen, August 7th, 2019 – MC2 Therapeutics A/S, a ...

READ FULL ARTICLE

© mc2 therapeutics 2020